

Andrew Lloyd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/611511/publications.pdf>

Version: 2024-02-01

418
papers

25,209
citations

9234

74
h-index

9073

144
g-index

436
all docs

436
docs citations

436
times ranked

20071
citing authors

#	ARTICLE	IF	CITATIONS
1	“That was quick, simple, and easy” Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison. <i>International Journal of Drug Policy</i> , 2022, 99, 103456.	1.6	14
2	Peripheral NF- κ B dysregulation in people with schizophrenia drives inflammation: putative anti-inflammatory functions of NF- κ B kinases. <i>Translational Psychiatry</i> , 2022, 12, 21.	2.4	12
3	Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T κ cell responses. <i>Cell Reports</i> , 2022, 38, 110345.	2.9	30
4	A research agenda for post-COVID-19 fatigue. <i>Journal of Psychosomatic Research</i> , 2022, 154, 110726.	1.2	16
5	Interleukin-17 contributes to Ross River virus-induced arthritis and myositis. <i>PLoS Pathogens</i> , 2022, 18, e1010185.	2.1	6
6	Evolution of within-host variants of the hepatitis C virus. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105242.	1.0	0
7	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The STOp-C Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 1809-1819.	2.9	11
8	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	2.6	10
9	The role of low-income and middle-income country prisons in eliminating hepatitis C. <i>Lancet Public Health</i> , The, 2022, 7, e578-e579.	4.7	3
10	The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting. <i>Addiction</i> , 2021, 116, 1162-1171.	1.7	6
11	Regulation of the Acute Sickness Response by the P2RX7 Receptor. <i>Journal of Infectious Diseases</i> , 2021, 224, 914-920.	1.9	4
12	CD73+ CD127 ^{high} Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 912.	1.8	2
13	Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study. <i>Brain, Behavior, & Immunity - Health</i> , 2021, 10, 100189.	1.3	9
14	People in prison who inject drugs: who is trusted when it comes to information about hepatitis C?. <i>Addiction Research and Theory</i> , 2021, 29, 247-254.	1.2	3
15	Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis. <i>PLoS ONE</i> , 2021, 16, e0245896.	1.1	10
16	The severity of the pathogen-induced acute sickness response is affected by polymorphisms in genes of the NLRP3 inflammasome pathway. <i>Brain, Behavior, and Immunity</i> , 2021, 93, 186-193.	2.0	5
17	Adaptation of Oxford Nanopore technology for hepatitis C whole genome sequencing and identification of within-host viral variants. <i>BMC Genomics</i> , 2021, 22, 148.	1.2	14
18	Human CD8 T κ stem cell memory subsets phenotypic and functional characterization are defined by expression of CD122 or CXCR3. <i>European Journal of Immunology</i> , 2021, 51, 1732-1747.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. <i>Cell Reports Medicine</i> , 2021, 2, 100228.	3.3	66
20	Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 391-400.	3.7	37
21	Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity. <i>Viruses</i> , 2021, 13, 983.	1.5	5
22	Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 533-546.	3.7	48
23	Optimisation and validation of a new method for antibody dependent cellular phagocytosis in hepatitis C virus infection. <i>Journal of Immunological Methods</i> , 2021, 495, 113087.	0.6	6
24	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP Treatment as Prevention Study in Prisons. <i>Hepatology</i> , 2021, 74, 2366-2379.	3.6	9
25	Subjective sleep quality and characteristics across the menstrual cycle in women with and without Generalized Anxiety Disorder. <i>Journal of Psychosomatic Research</i> , 2021, 148, 110570.	1.2	4
26	Long COVID and Post-infective Fatigue Syndrome: A Review. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab440.	0.4	128
27	Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel. <i>International Journal of Drug Policy</i> , 2021, 98, 103379.	1.6	3
28	Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. <i>Clinical Infectious Diseases</i> , 2020, 70, 123-131.	2.9	7
29	The impact of childhood trauma on psychosocial functioning and physical health in a non-clinical community sample of young adults. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 185-194.	1.3	36
30	Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study. <i>Addiction</i> , 2020, 115, 901-913.	1.7	21
31	Physical and mental fatigue across the menstrual cycle in women with and without generalised anxiety disorder. <i>Hormones and Behavior</i> , 2020, 118, 104667.	1.0	26
32	B cell immunodominance in primary hepatitis C virus infection. <i>Journal of Hepatology</i> , 2020, 72, 670-679.	1.8	21
33	Single molecule, near full-length genome sequencing of dengue virus. <i>Scientific Reports</i> , 2020, 10, 18196.	1.6	11
34	Parasympathetic activity is reduced during slow-wave sleep, but not resting wakefulness, in patients with chronic fatigue syndrome. <i>Journal of Clinical Sleep Medicine</i> , 2020, 16, 19-28.	1.4	14
35	Incident hepatitis B virus infection and immunisation uptake in Australian prison inmates. <i>Vaccine</i> , 2020, 38, 3255-3260.	1.7	9
36	Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. <i>Hepatology Communications</i> , 2020, 4, 904-915.	2.0	4

#	ARTICLE	IF	CITATIONS
37	Anti-Envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1012-1021.	1.0	1
38	Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study. <i>Cancer Epidemiology</i> , 2020, 67, 101773.	0.8	2
39	Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting. <i>International Journal of Drug Policy</i> , 2020, 77, 102693.	1.6	12
40	Cognitive decline may not be adequately captured in economic evaluations of multiple sclerosis: are new treatments being undervalued?. <i>Current Medical Research and Opinion</i> , 2020, 36, 609-611.	0.9	8
41	Chronic fatigue syndrome: progress and possibilities. <i>Medical Journal of Australia</i> , 2020, 212, 428-433.	0.8	40
42	Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection. <i>Viruses</i> , 2020, 12, 75.	1.5	19
43	Violence and hepatitis C transmission in prison—A modified social ecological model. <i>PLoS ONE</i> , 2020, 15, e0243106.	1.1	4
44	Contribution of individual psychological and psychosocial factors to symptom severity and time-to-recovery after naturally-occurring acute infective illness: The Dubbo Infection Outcomes Study (DIOS). <i>Brain, Behavior, and Immunity</i> , 2019, 82, 76-83.	2.0	10
45	Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus. <i>Journal of Virology</i> , 2019, 93, .	1.5	9
46	S33. REDUCTION IN PERIPHERAL C-REACTIVE PROTEIN LEVELS WITH CANAKINUMAB ADMINISTRATION IS RELATED TO REDUCED POSITIVE SYMPTOM SEVERITY IN PATIENTS WITH SCHIZOPHRENIA AND INFLAMMATION. <i>Schizophrenia Bulletin</i> , 2019, 45, S318-S318.	2.3	6
47	Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies. <i>Scientific Reports</i> , 2019, 9, 13300.	1.6	28
48	107. Reduction in Peripheral C-Reactive Protein Levels With Canakinumab Administration is Related to Reduced Positive Symptom Severity in Patients With Schizophrenia and Inflammation. <i>Biological Psychiatry</i> , 2019, 85, S44-S45.	0.7	0
49	Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. <i>Journal of Hepatology</i> , 2019, 70, 839-846.	1.8	80
50	A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers. <i>Journal of Immunological Methods</i> , 2019, 472, 65-74.	0.6	15
51	Severe Eosinophilic Meningoencephalitis Secondary to Suspected Neuroangiostrongyliasis with a Good Clinical Outcome. <i>Case Reports in Infectious Diseases</i> , 2019, 2019, 1-4.	0.2	1
52	Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. <i>PLoS Pathogens</i> , 2019, 15, e1007772.	2.1	45
53	Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting. <i>International Journal of Drug Policy</i> , 2019, 72, 123-128.	1.6	40
54	Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. <i>Infection, Genetics and Evolution</i> , 2019, 71, 36-41.	1.0	14

#	ARTICLE	IF	CITATIONS
55	A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015. <i>Journal of the International AIDS Society</i> , 2019, 22, e25222.	1.2	6
56	Response to Commentary: "Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, and Chronic Fatigue: Three Distinct Entities Requiring Complete Different Approaches". <i>Current Rheumatology Reports</i> , 2019, 21, 22.	2.1	0
57	Scale-up of hepatitis C treatment in prisons is key to national elimination. <i>Medical Journal of Australia</i> , 2019, 210, 391.	0.8	14
58	Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 91.	1.8	10
59	The Invisible Burden of Chronic Fatigue in the Community: a Narrative Review. <i>Current Rheumatology Reports</i> , 2019, 21, 5.	2.1	10
60	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. <i>Liver International</i> , 2019, 39, 20-30.	1.9	88
61	Genomic variability of within-host hepatitis C variants in acute infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 476-484.	1.0	6
62	Chemokine-Regulated Recruitment of Antigen-Specific T-Cell Subpopulations to the Liver in Acute and Chronic Hepatitis C Infection. <i>Journal of Infectious Diseases</i> , 2019, 219, 1430-1438.	1.9	11
63	Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 83-92.	1.0	58
64	The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. <i>Clinical Infectious Diseases</i> , 2018, 66, 20-28.	2.9	21
65	B-cell receptor reconstruction from single-cell RNA-seq with VDJpuzzle. <i>Bioinformatics</i> , 2018, 34, 2846-2847.	1.8	87
66	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. <i>International Journal of Drug Policy</i> , 2018, 54, 18-25.	1.6	46
67	The international collaborative on fatigue following infection (COFFI). <i>Fatigue: Biomedicine, Health and Behavior</i> , 2018, 6, 106-121.	1.2	21
68	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. <i>Journal of Medical Virology</i> , 2018, 90, 120-130.	2.5	6
69	Understanding the Determinants of BnAb Induction in Acute HCV Infection. <i>Viruses</i> , 2018, 10, 659.	1.5	15
70	Cluster of invasive <i>Mycobacteria chimaera</i> infections following cardiac surgery demonstrating novel clinical features and risks of aortic valve replacement. <i>Internal Medicine Journal</i> , 2018, 48, 1514-1520.	0.5	9
71	Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study. <i>Journal of Hepatology</i> , 2018, 68, S187-S188.	1.8	2
72	Personalised relaxation practice to improve sleep and functioning in patients with chronic fatigue syndrome and depression: study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 371.	0.7	2

#	ARTICLE	IF	CITATIONS
73	Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1526-1532.	1.0	44
74	A161 ONGOING INCIDENT HEPATITIC C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 278-280.	0.1	0
75	Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. <i>PLoS ONE</i> , 2018, 13, e0192763.	1.1	20
76	Immunopathogenesis of HIV Coinfections. , 2018, , 1083-1096.		0
77	Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. <i>Infection, Genetics and Evolution</i> , 2017, 49, 88-96.	1.0	8
78	Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment. <i>Scientific Reports</i> , 2017, 7, 41719.	1.6	12
79	Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 733-741.	1.0	61
80	Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. <i>Clinical Infectious Diseases</i> , 2017, 64, 860-869.	2.9	61
81	Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis. <i>Supportive Care in Cancer</i> , 2017, 25, 2871-2879.	1.0	6
82	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 74-84.	0.6	45
83	Randomised controlled trial of online continuing education for health professionals to improve the management of chronic fatigue syndrome: a study protocol. <i>BMJ Open</i> , 2017, 7, e014133.	0.8	5
84	Cytokine signature in chronic fatigue syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9435-E9435.	3.3	1
85	Impact of sequencing depth and read length on single cell RNA sequencing data of T cells. <i>Scientific Reports</i> , 2017, 7, 12781.	1.6	60
86	Cognitive remediation training improves performance in patients with chronic fatigue syndrome. <i>Psychiatry Research</i> , 2017, 257, 400-405.	1.7	14
87	Immune dysregulation in patients with carpal tunnel syndrome. <i>Scientific Reports</i> , 2017, 7, 8218.	1.6	16
88	Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study. <i>Journal of Hepatology</i> , 2017, 66, S274.	1.8	3
89	Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study. <i>Journal of Hepatology</i> , 2017, 66, S488.	1.8	0
90	A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit. <i>Journal of Hepatology</i> , 2017, 66, S495.	1.8	0

#	ARTICLE	IF	CITATIONS
91	Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance. <i>Journal of Hepatology</i> , 2017, 66, S323.	1.8	0
92	[P3â€“225]: SYSTEMATIC REVIEW OF ASSOCIATIONS BETWEEN BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA AND CYTOKINES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1024.	0.4	0
93	Autonomic nervous system function, activity patterns, and sleep after physical or cognitive challenge in people with chronic fatigue syndrome. <i>Journal of Psychosomatic Research</i> , 2017, 103, 91-94.	1.2	16
94	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	1.6	54
95	Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC ³ Study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 43-52.	1.0	14
96	Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 37-42.	1.0	11
97	A molecular transmission network of recent hepatitis C infection in people with and without <scp>HIV</scp>: Implications for targeted treatment strategies. <i>Journal of Viral Hepatitis</i> , 2017, 24, 404-411.	1.0	23
98	Understanding the complex evolution of rapidly mutating viruses with deep sequencing: Beyond the analysis of viral diversity. <i>Virus Research</i> , 2017, 239, 43-54.	1.1	19
99	Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. <i>Hepatology Communications</i> , 2017, 1, 379-390.	2.0	26
100	Unravelling the complexities of virus and host interactions in the Viral Immunology Systems Program, NHMRC, ACH2, National Institutes of Health. <i>Impact</i> , 2017, 2017, 34-36.	0.0	0
101	The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High?. <i>PLoS ONE</i> , 2016, 11, e0162399.	1.1	23
102	Gene Expression in Response to Exercise in Patients with Chronic Fatigue Syndrome: A Pilot Study. <i>Frontiers in Physiology</i> , 2016, 7, 421.	1.3	8
103	Hepatitis C in Australian prisons: a national needs assessment. <i>International Journal of Prisoner Health</i> , 2016, 12, 3-16.	0.5	9
104	Natural killer cells in highly exposed hepatitis C seronegative injecting drug users. <i>Journal of Viral Hepatitis</i> , 2016, 23, 464-472.	1.0	3
105	Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans. <i>Hepatology</i> , 2016, 64, 2264-2265.	3.6	4
106	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. <i>Liver International</i> , 2016, 36, 1774-1782.	1.9	8
107	Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1855-1861.	1.8	12
108	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 465-465.	0.6	5

#	ARTICLE	IF	CITATIONS
109	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 317-327.	3.7	80
110	A method for near full-length amplification and sequencing for six hepatitis C virus genotypes. <i>BMC Genomics</i> , 2016, 17, 247.	1.2	52
111	The natural history of acute Q fever: a prospective Australian cohort. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 661-668.	0.2	6
112	Hepatitis C-specific effector and regulatory CD4 T cell responses are associated with the outcomes of primary infection. <i>Journal of Viral Hepatitis</i> , 2016, 23, 985-993.	1.0	13
113	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. <i>Journal of Infectious Diseases</i> , 2016, 214, 1383-1389.	1.9	16
114	Outcomes and predictors of response from an optimised, multidisciplinary intervention for chronic fatigue states. <i>Internal Medicine Journal</i> , 2016, 46, 1421-1429.	0.5	14
115	The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. <i>Drug and Alcohol Dependence</i> , 2016, 169, 156-162.	1.6	10
116	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 425-434.	0.6	6
117	Fatigue Exacerbation by Interval or Continuous Exercise in Chronic Fatigue Syndrome. <i>Medicine and Science in Sports and Exercise</i> , 2016, 48, 1875-1885.	0.2	14
118	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. <i>Virology Journal</i> , 2016, 13, 32.	1.4	10
119	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. <i>BMC Infectious Diseases</i> , 2016, 16, 241.	1.3	5
120	Neurocognitive improvements after best-practice intervention for chronic fatigue syndrome: Preliminary evidence of divergence between objective indices and subjective perceptions. <i>Comprehensive Psychiatry</i> , 2016, 66, 166-175.	1.5	11
121	Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial. <i>Journal of Clinical Virology</i> , 2016, 74, 66-72.	1.6	11
122	Linking the T cell receptor to the single cell transcriptome in antigen-specific human T cells. <i>Immunology and Cell Biology</i> , 2016, 94, 604-611.	1.0	118
123	HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. <i>Infection, Genetics and Evolution</i> , 2016, 37, 252-258.	1.0	13
124	Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw024.	0.4	1
125	Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. <i>PLoS ONE</i> , 2016, 11, e0150655.	1.1	15
126	Capturing Activity Pacing in People with Chronic Fatigue Syndrome Using Actigraphy. <i>Medicine and Science in Sports and Exercise</i> , 2016, 48, 118.	0.2	0

#	ARTICLE	IF	CITATIONS
127	Hepatitis B immunity in Australia: a comparison of national and prisoner population serosurveys. <i>Epidemiology and Infection</i> , 2015, 143, 2813-2821.	1.0	9
128	Co-evolving mutations in hepatitis C virus in the context of immune escape against neutralising antibody responses - A bioinformatic workflow for the analysis of co-evolving mutations in viral genomes. , 2015, , .		0
129	Acquiring hepatitis C in prison: the social organisation of injecting risk. <i>Harm Reduction Journal</i> , 2015, 12, 10.	1.3	21
130	Physical Activity And Sleep Patterns Following Physical And Cognitive Challenge In Patients With Chronic Fatigue Syndrome.. <i>Medicine and Science in Sports and Exercise</i> , 2015, 47, 58.	0.2	0
131	Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. <i>Journal of Viral Hepatitis</i> , 2015, 22, 1020-1032.	1.0	10
132	Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. <i>Viruses</i> , 2015, 7, 5206-5224.	1.5	102
133	Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. <i>PLoS ONE</i> , 2015, 10, e0122232.	1.1	41
134	Transmitted/Founder Viruses Rapidly Escape from CD8 ⁺ T Cell Responses in Acute Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2015, 89, 5478-5490.	1.5	31
135	The long wait for a breakthrough in chronic fatigue syndrome. <i>BMJ, The</i> , 2015, 350, h2087-h2087.	3.0	11
136	Recommandations pour la prise en charge de lâ€™infection par le virus de lâ€™hépatite C chez les usagers de drogues par injection. <i>International Journal of Drug Policy</i> , 2015, , 101669.	1.6	0
137	Capturing the post-exertional exacerbation of fatigue following physical and cognitive challenge in patients with chronic fatigue syndrome. <i>Journal of Psychosomatic Research</i> , 2015, 79, 537-549.	1.2	34
138	Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral. <i>International Journal of Drug Policy</i> , 2015, , 101671.	1.6	0
139	Resistance to hepatitis C virus: potential genetic and immunological determinants. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 451-460.	4.6	17
140	A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. <i>Journal of Epidemiology and Community Health</i> , 2015, 69, 745-752.	2.0	21
141	Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfectionâ€”the InC ³ Study. <i>Journal of Infectious Diseases</i> , 2015, 212, 1407-1419.	1.9	82
142	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC ³ study. <i>Journal of Viral Hepatitis</i> , 2015, 22, 708-717.	1.0	13
143	Mixed HCV infection and reinfection in people who inject drugsâ€™ impact on therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 218-230.	8.2	79
144	Herpes Simplex Virus Type 2â€™ Infected Dendritic Cells Produce TNF-Î±, Which Enhances CCR5 Expression and Stimulates HIV Production from Adjacent Infected Cells. <i>Journal of Immunology</i> , 2015, 194, 4438-4445.	0.4	30

#	ARTICLE	IF	CITATIONS
145	Characterisation of the cytokine milieu associated with the up-regulation of IL6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders. <i>Liver International</i> , 2015, 35, 463-472.	1.9	5
146	The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry. <i>Journal of Biological Chemistry</i> , 2015, 290, 25946-25959.	1.6	128
147	Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012. <i>Emerging Infectious Diseases</i> , 2015, 21, 765-774.	2.0	37
148	Recommendations for the management of hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1028-1038.	1.6	159
149	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. <i>International Journal of Drug Policy</i> , 2015, 26, 976-983.	1.6	44
150	Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2015, 20, 440-446.	4.1	371
151	Erratum to "A Bioinformatics Pipeline for the Analyses of Viral Escape Dynamics and Host Immune Responses during an Infection". <i>BioMed Research International</i> , 2014, 2014, 1-2.	0.9	1
152	Enhancing hepatitis C treatment in the custodial setting: a national roadmap. <i>Medical Journal of Australia</i> , 2014, 200, 15-16.	0.8	11
153	Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS study. <i>Medical Journal of Australia</i> , 2014, 201, 326-329.	0.8	101
154	A Bioinformatics Pipeline for the Analyses of Viral Escape Dynamics and Host Immune Responses during an Infection. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	9
155	A prospective study of hepatitis C incidence in Australian prisoners. <i>Addiction</i> , 2014, 109, 1695-1706.	1.7	58
156	Regulation of T cell recruitment and inflammation in the human immunodeficiency virus/hepatitis C virus coinfecting liver. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1535-1543.	1.4	0
157	Exploration of genetically determined resistance against hepatitis C infection in high-risk injecting drug users. <i>Journal of Viral Hepatitis</i> , 2014, 21, e65-73.	1.0	14
158	Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn. <i>Hepatology</i> , 2014, 60, 2127-2128.	3.6	14
159	Characterization of Fatigue States in Medicine and Psychiatry by Structured Interview. <i>Psychosomatic Medicine</i> , 2014, 76, 379-388.	1.3	20
160	Immunopathogenesis of HIV Coinfections. , 2014, , 1-15.		0
161	The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. <i>Hepatology</i> , 2014, 59, 109-120.	3.6	320
162	Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. <i>Supportive Care in Cancer</i> , 2014, 22, 1233-1242.	1.0	33

#	ARTICLE	IF	CITATIONS
163	Protection against hepatitis C infection via NK cells in highly-exposed uninfected injecting drug users. <i>Journal of Hepatology</i> , 2014, 61, 738-745.	1.8	23
164	Positioning of leukocyte subsets in the portal and lobular compartments of hepatitis C virus-infected liver correlates with local chemokine expression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 860-869.	1.4	18
165	Evidence that hepatitis C virus genome partly controls infection outcome. <i>Evolutionary Applications</i> , 2014, 7, 533-547.	1.5	4
166	Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. <i>Journal of Clinical Virology</i> , 2014, 61, 430-434.	1.6	8
167	Dynamics of HCV RNA levels during acute hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2014, 86, 1722-1729.	2.5	26
168	Neurocognitive disturbances associated with acute infectious mononucleosis, Ross River fever and Q fever: A preliminary investigation of inflammatory and genetic correlates. <i>Brain, Behavior, and Immunity</i> , 2014, 36, 207-214.	2.0	20
169	A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners. <i>PLoS ONE</i> , 2014, 9, e87564.	1.1	38
170	Per-Event Probability of Hepatitis C Infection during Sharing of Injecting Equipment. <i>PLoS ONE</i> , 2014, 9, e100749.	1.1	14
171	Exacerbation of Fatigue following Interval and Continuous Exercise in Patients with Chronic Fatigue Syndrome. <i>Medicine and Science in Sports and Exercise</i> , 2014, 46, 684.	0.2	0
172	Reliability revisited: Autonomic responses in the context of everyday well-being. <i>International Journal of Cardiology</i> , 2013, 166, 743-745.	0.8	13
173	Measurement of neopterin, TGF- β 1 and ACE in the exhaled breath condensate of patients with sarcoidosis. <i>Journal of Breath Research</i> , 2013, 7, 046003.	1.5	20
174	Rare occurrence of occult hepatitis C virus in apparently uninfected injecting drug users: a two-centre, masked, case-control study. <i>Journal of Viral Hepatitis</i> , 2013, 20, 725-728.	1.0	9
175	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. <i>Hepatology</i> , 2013, 57, 2124-2134.	3.6	61
176	<sc>HIV</sc> and co-infections. <i>Immunological Reviews</i> , 2013, 254, 114-142.	2.8	116
177	Enhancing Assessment and Treatment of Hepatitis C in the Custodial Setting. <i>Clinical Infectious Diseases</i> , 2013, 57, S70-S74.	2.9	36
178	Safety and Effectiveness of a Nurse-Led Outreach Program for Assessment and Treatment of Chronic Hepatitis C in the Custodial Setting. <i>Clinical Infectious Diseases</i> , 2013, 56, 1078-1084.	2.9	109
179	Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements. <i>Clinical Infectious Diseases</i> , 2013, 57, 1014-1020.	2.9	97
180	Mood disturbance after infection. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 1152-1164.	1.3	16

#	ARTICLE	IF	CITATIONS
181	Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. <i>International Journal of Epidemiology</i> , 2013, 42, 1649-1659.	0.9	48
182	Maintenance of T _H 1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1770-1781.	1.4	17
183	Apology. <i>Journal of Internal Medicine</i> , 2013, 273, 628-628.	2.7	0
184	Correlates and characteristics of hepatitis C virus-specific T _H 1 cell immunity in exposed uninfected high-risk prison inmates. <i>Journal of Viral Hepatitis</i> , 2013, 20, e96-106.	1.0	15
185	Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection. <i>PLoS ONE</i> , 2013, 8, e80003.	1.1	9
186	Treatment outcomes for Indigenous and non-Indigenous inmates with hepatitis C in New South Wales prisons. <i>Medical Journal of Australia</i> , 2013, 199, 464-464.	0.8	1
187	Fatigue after infection: aetiology and pathophysiology. <i>Microbiology Australia</i> , 2013, 34, 142.	0.1	0
188	Post-cancer fatigue is not associated with immune activation or altered cytokine production. <i>Annals of Oncology</i> , 2012, 23, 2890-2895.	0.6	18
189	Reply to A. Giacalone et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 4175-4176.	0.8	0
190	Impaired Hepatitis C Virus (HCV)-Specific Interferon- β Responses in Individuals With HIV Who Acquire HCV Infection: Correlation With CD4+ T-Cell Counts. <i>Journal of Infectious Diseases</i> , 2012, 206, 1568-1576.	1.9	21
191	Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1805-1812.	0.8	114
192	Cytomegalovirus Infection During Pregnancy With Maternofetal Transmission Induces a Proinflammatory Cytokine Bias in Placenta and Amniotic Fluid. <i>Journal of Infectious Diseases</i> , 2012, 205, 1305-1310.	1.9	73
193	Virological responses during treatment for recent hepatitis C virus. <i>Aids</i> , 2012, 26, 1653-1661.	1.0	27
194	Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 408-414.	4.6	186
195	Next generation deep sequencing and vaccine design: today and tomorrow. <i>Trends in Biotechnology</i> , 2012, 30, 443-452.	4.9	59
196	Peripheral blood responses to specific antigens and CD28 in sarcoidosis. <i>Respiratory Medicine</i> , 2012, 106, 701-709.	1.3	35
197	Paradoxical Embolus and Endophthalmitis. <i>Ophthalmology</i> , 2012, 119, 424-424.e1.	2.5	0
198	Genetic associations of fatigue and other symptom domains of the acute sickness response to infection. <i>Brain, Behavior, and Immunity</i> , 2012, 26, 552-558.	2.0	56

#	ARTICLE	IF	CITATIONS
199	Impact of Treatment Attributes of Peginterferon for Hepatitis C on Quality of Life and Treatment Preference. <i>Health Outcomes Research in Medicine</i> , 2012, 3, e153-e167.	0.6	4
200	Reduced Cardiac Vagal Modulation Impacts on Cognitive Performance in Chronic Fatigue Syndrome. <i>PLoS ONE</i> , 2012, 7, e49518.	1.1	72
201	Occult infection with hepatitis C virus: friend or foe?. <i>Immunology and Cell Biology</i> , 2012, 90, 763-773.	1.0	13
202	Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. <i>Hepatology</i> , 2012, 55, 1058-1069.	3.6	82
203	A controversial consensus "comment on article by Broderick et al". <i>Journal of Internal Medicine</i> , 2012, 271, 29-31.	2.7	12
204	Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney. <i>Australian and New Zealand Journal of Public Health</i> , 2012, 36, 351-356.	0.8	15
205	A novel assay for detection of hepatitis C virus-specific effector CD4+ T cells via co-expression of CD25 and CD134. <i>Journal of Immunological Methods</i> , 2012, 375, 148-158.	0.6	29
206	Effect of pegylated interferon- α 2a treatment on mental health during recent hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 957-965.	1.4	38
207	Modafinil for fatigue associated with docetaxel-based chemotherapy: A randomized controlled trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 211-211.	0.8	0
208	Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. <i>Journal of Hepatology</i> , 2011, 55, 76-85.	1.8	53
209	Sleep-Wake Behavior in Chronic Fatigue Syndrome. <i>Sleep</i> , 2011, 34, 671-678.	0.6	47
210	Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. <i>Journal of Viral Hepatitis</i> , 2011, 18, 549-561.	1.0	54
211	Alterations in Immune Function are Associated with Liver Enzyme Elevation in HIV and HCV Co-infection after Commencement of Combination Antiretroviral Therapy. <i>Journal of Clinical Immunology</i> , 2011, 31, 1079-1083.	2.0	10
212	The long and the short of interferon-gamma-inducible protein 10 in hepatitis C virus infection. <i>Hepatology</i> , 2011, 54, 1875-1879.	3.6	3
213	Patterns and Characteristics of Hepatitis C Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C. <i>Clinical Infectious Diseases</i> , 2011, 52, 803-811.	2.9	95
214	If I Am in the Mood, I Enjoy It: An Exploration of Cancer-Related Fatigue and Sexual Functioning in Women with Breast Cancer. <i>Oncologist</i> , 2011, 16, 1333-1344.	1.9	84
215	Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virus Infection. <i>PLoS Pathogens</i> , 2011, 7, e1002243.	2.1	201
216	Concordance of CCR5 Genotypes that Influence Cell-Mediated Immunity and HIV-1 Disease Progression Rates. <i>Journal of Infectious Diseases</i> , 2011, 203, 263-272.	1.9	29

#	ARTICLE	IF	CITATIONS
217	Peripheral Blood Gene Expression in Postinfective Fatigue Syndrome Following From Three Different Triggering Infections. <i>Journal of Infectious Diseases</i> , 2011, 204, 1632-1640.	1.9	26
218	Reduced heart rate variability predicts poor sleep quality in a caseâ€“control study of chronic fatigue syndrome. <i>Experimental Brain Research</i> , 2010, 204, 71-78.	0.7	102
219	Incidence and risk for acute hepatitis C infection during imprisonment in Australia. <i>European Journal of Epidemiology</i> , 2010, 25, 143-148.	2.5	74
220	Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. <i>BMC Public Health</i> , 2010, 10, 633.	1.2	69
221	Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 1216-1224.	3.6	156
222	Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. <i>Hepatology</i> , 2010, 52, 1564-1572.	3.6	88
223	Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHVâ€“6 in postâ€“infective fatigue syndrome. <i>Journal of Medical Virology</i> , 2010, 82, 1684-1688.	2.5	63
224	Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. <i>Medical Journal of Australia</i> , 2010, 192, 496-500.	0.8	43
225	The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection. <i>Gut</i> , 2010, 59, 397-404.	6.1	29
226	Serum Cytokine Levels in Postinfective Fatigue Syndrome. <i>Clinical Infectious Diseases</i> , 2010, 50, 278-279.	2.9	15
227	Comment on â€œDetection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndromeâ€“. <i>Science</i> , 2010, 328, 825-825.	6.0	11
228	Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 123-135.e2.	0.6	157
229	Autonomic hyper-vigilance in post-infective fatigue syndrome. <i>Biological Psychology</i> , 2010, 85, 97-103.	1.1	20
230	Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. <i>Drug and Alcohol Dependence</i> , 2010, 107, 244-249.	1.6	33
231	Influence of fatigue after breast cancer adjuvant therapy on health care utilization and perceived needs.. <i>Journal of Clinical Oncology</i> , 2010, 28, 9047-9047.	0.8	1
232	What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2010, 28, 605-605.	0.8	22
233	Are common childhood or adolescent infections risk factors for schizophrenia and other psychotic disorders?. <i>Medical Journal of Australia</i> , 2009, 190, S17.	0.8	26
234	Characteristics and Treatment Outcomes among HIVâ€“Infected Individuals in the Australian Trial in Acute Hepatitis C. <i>Clinical Infectious Diseases</i> , 2009, 48, 650-658.	2.9	109

#	ARTICLE	IF	CITATIONS
235	Immunological determinants of the outcomes from primary hepatitis C infection. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 733-756.	2.4	48
236	Are Chronic Fatigue and Chronic Fatigue Syndrome Valid Clinical Entities Across Countries and Health-Care Settings?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 25-35.	1.3	52
237	Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHIC Study. <i>Canadian Journal of Addiction</i> , 2009, 1, 33.	0.2	0
238	A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. <i>Hepatology</i> , 2008, 48, 374-384.	3.6	71
239	Neuropsychiatric symptoms and immune activation in patients with genital herpes. <i>Acta Neuropsychiatrica</i> , 2008, 20, 145-151.	1.0	3
240	Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. <i>Clinical and Experimental Immunology</i> , 2008, 87, 76-79.	1.1	89
241	Differences in amniotic fluid and maternal serum cytokine levels in early midtrimester women without evidence of infection. <i>Cytokine</i> , 2008, 44, 78-84.	1.4	86
242	How Does Patients'™ Quality of Life Guide Their Preferences Regarding Aspects of Asthma Therapy?. <i>Patient</i> , 2008, 1, 309-316.	1.1	6
243	Cytokine Polymorphisms Have a Synergistic Effect on Severity of the Acute Sickness Response to Infection. <i>Clinical Infectious Diseases</i> , 2008, 47, 1418-1425.	2.9	85
244	Postinfective Fatigue Syndrome Is Not Associated with Altered Cytokine Production. <i>Clinical Infectious Diseases</i> , 2007, 45, 732-735.	2.9	63
245	Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al.. <i>Aids</i> , 2007, 21, 2112-2113.	1.0	62
246	Substantial Improvements in Performance Indicators Achieved in a Peripheral Blood Mononuclear Cell Cryopreservation Quality Assurance Program Using Single Donor Samples. <i>Vaccine Journal</i> , 2007, 14, 52-59.	3.2	19
247	Gene Expression Correlates of Postinfective Fatigue Syndrome after Infectious Mononucleosis. <i>Journal of Infectious Diseases</i> , 2007, 196, 56-66.	1.9	23
248	Fatigue: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2007, 25, 5685-5696.	1.7	14
249	Changes in Toll-like Receptor (TLR)-2 and TLR4 Expression and Function but Not Polymorphisms Are Associated with Acute Anterior Uveitis. , 2007, 48, 1711.		58
250	CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. <i>Nature Immunology</i> , 2007, 8, 1324-1336.	7.0	152
251	Polymorphisms in Toll-like receptors-2 and -4 are not associated with disease manifestations in acute Q fever. <i>Genes and Immunity</i> , 2007, 8, 699-702.	2.2	21
252	Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. <i>Immunology and Cell Biology</i> , 2007, 85, 24-32.	1.0	55

#	ARTICLE	IF	CITATIONS
253	A critical role for CCL2 and CCL3 chemokines in the regulation of polymorphonuclear neutrophils recruitment during corneal infection in mice. <i>Immunology and Cell Biology</i> , 2007, 85, 525-531.	1.0	39
254	A murine model of appendicitis and the impact of inflammation on appendiceal lymphocyte constituents. <i>Clinical and Experimental Immunology</i> , 2007, 150, 169-178.	1.1	30
255	The Experience of Cancer-Related Fatigue and Chronic Fatigue Syndrome: A Qualitative and Comparative Study. <i>Journal of Pain and Symptom Management</i> , 2007, 34, 126-135.	0.6	59
256	Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr Virus. <i>BMC Infectious Diseases</i> , 2006, 6, 15.	1.3	58
257	Protective immunity against hepatitis C virus infection. <i>Immunology and Cell Biology</i> , 2006, 84, 239-249.	1.0	30
258	Correlation of psycho-neuroendocrine-immune (PNI) gene expression with symptoms of acute infectious mononucleosis. <i>Brain Research</i> , 2006, 1068, 1-6.	1.1	9
259	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. <i>BMC Cancer</i> , 2006, 6, 240.	1.1	79
260	Desbuquois syndrome in three sisters with significantly different lengths of survival. <i>American Journal of Medical Genetics, Part A</i> , 2006, 140A, 1253-1255.	0.7	2
261	Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2006, 333, 575.	2.4	634
262	Exploration of the gene expression correlates of chronic unexplained fatigue using factor analysis. <i>Pharmacogenomics</i> , 2006, 7, 441-454.	0.6	18
263	Prolonged Illness after Infectious Mononucleosis Is Associated with Altered Immunity but Not with Increased Viral Load. <i>Journal of Infectious Diseases</i> , 2006, 193, 664-671.	1.9	63
264	Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-alpha and ribavirin treatment among patients with chronic hepatitis C virus infection*. <i>Journal of Viral Hepatitis</i> , 2005, 12, 125-129.	1.0	14
265	Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. <i>Clinical and Experimental Immunology</i> , 2005, 139, 411-420.	1.1	46
266	Immune response genes in the post-Q-fever fatigue syndrome, Q fever endocarditis and uncomplicated acute primary Q fever. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 565-574.	0.2	27
267	Does genotype mask the relationship between psychological factors and immune function?. <i>Brain, Behavior, and Immunity</i> , 2005, 19, 147-152.	2.0	8
268	To exercise or not to exercise in chronic fatigue syndrome? No longer a question. <i>Medical Journal of Australia</i> , 2004, 180, 437-438.	0.8	8
269	To exercise or not to exercise in chronic fatigue syndrome?. <i>Medical Journal of Australia</i> , 2004, 181, 578-580.	0.8	1
270	Clearance of Hepatitis C Viremia Associated with Cellular Immunity in the Absence of Seroconversion in the Hepatitis C Incidence and Transmission in Prisons Study Cohort. <i>Journal of Infectious Diseases</i> , 2004, 189, 1846-1855.	1.9	147

#	ARTICLE	IF	CITATIONS
271	CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. <i>Gut</i> , 2004, 53, 1287-1294.	6.1	63
272	Prevalence of Production of Virus-Specific Interferon- β among Seronegative Hepatitis C-Resistant Subjects Reporting Injection Drug Use. <i>Journal of Infectious Diseases</i> , 2004, 190, 1093-1097.	1.9	51
273	A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies, PEHRG214, in HIV-1-Infected Individuals. <i>HIV Clinical Trials</i> , 2004, 5, 91-98.	2.0	8
274	Risk Factors for Hepatitis C Infection and Perception of Antibody Status among Male Prison Inmates in the Hepatitis C Incidence and Transmission in Prisons Study Cohort, Australia. <i>Journal of Urban Health</i> , 2004, 81, 448-452.	1.8	21
275	Fatigue and psychological distress – exploring the relationship in women treated for breast cancer. <i>European Journal of Cancer</i> , 2004, 40, 1689-1695.	1.3	54
276	The relationship between distress and the development of a primary immune response to a novel antigen. <i>Brain, Behavior, and Immunity</i> , 2004, 18, 65-75.	2.0	49
277	Influences of Distress and Alcohol Consumption on the Development of a Delayed-Type Hypersensitivity Skin Test Response. <i>Psychosomatic Medicine</i> , 2004, 66, 614-619.	1.3	21
278	Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. <i>Psychological Medicine</i> , 2004, 34, 1289-1297.	2.7	175
279	Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care. <i>BMC Health Services Research</i> , 2003, 3, 1.	0.9	60
280	Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. <i>BMC Health Services Research</i> , 2003, 3, 25.	0.9	413
281	Therapeutic immunisation with COPV early genes by epithelial DNA delivery. <i>Virology</i> , 2003, 314, 630-635.	1.1	32
282	Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection. <i>Journal of Medical Virology</i> , 2003, 70, 617-623.	2.5	63
283	Multicentric Castleman's disease treated with antivirals and immunosuppressants. <i>Journal of Medical Virology</i> , 2003, 71, 399-403.	2.5	33
284	The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2003, 38, 349-356.	1.8	64
285	Role and regulation of CXC-chemokines in acute experimental keratitis. <i>Experimental Eye Research</i> , 2003, 76, 221-231.	1.2	40
286	Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. <i>Journal of Leukocyte Biology</i> , 2003, 74, 360-369.	1.5	211
287	Cutting Edge: Vasoactive Intestinal Peptide Acts as a Potent Suppressor of Inflammation In Vivo by Trans-Deactivating Chemokine Receptors. <i>Journal of Immunology</i> , 2003, 171, 4990-4994.	0.4	45
288	Regulation of MMPs and TIMPs by IL-1 β during Corneal Ulceration and Infection. , 2003, 44, 2020.		66

#	ARTICLE	IF	CITATIONS
289	Balance of Pro- and Anti-Inflammatory Cytokines Correlates with Outcome of Acute Experimental <i>Pseudomonas aeruginosa</i> Keratitis. <i>Infection and Immunity</i> , 2002, 70, 2187-2197.	1.0	62
290	Quantification of Hepatitis C Virus in Human Liver and Serum Samples by Using LightCycler Reverse Transcriptase PCR. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4346-4348.	1.8	45
291	Immunity against hepatitis C virus infection. <i>Lancet, The</i> , 2002, 360, 1020.	6.3	2
292	Acute Q Fever and Brachial Neuritis: Case Report and Literature Review. <i>Infection</i> , 2002, 30, 400-402.	2.3	4
293	Eotaxin Expression by Epithelial Cells and Plasma Cells in Chronic Asthma. <i>Laboratory Investigation</i> , 2002, 82, 495-504.	1.7	30
294	Intraepithelial DNA Immunisation with a Plasmid Encoding a Codon Optimised COPV E1 Gene Sequence, But Not the Wild-Type Gene Sequence Completely Protects against Mucosal Challenge with Infectious COPV in Beagles. <i>Virology</i> , 2002, 304, 451-459.	1.1	19
295	Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. <i>Medical Journal of Australia</i> , 2001, 174, 183-184.	0.8	57
296	What is Chronic Fatigue Syndrome? Heterogeneity Within an International Multicentre Study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2001, 35, 520-527.	1.3	106
297	Immunopathogenesis of hepatitis C virus infection. <i>Immunology and Cell Biology</i> , 2001, 79, 515-536.	1.0	74
298	Estimating progression to cirrhosis in chronic hepatitis C virus infection. <i>Hepatology</i> , 2001, 34, 809-816.	3.6	526
299	Expression of macrophage migration inhibitory factor during <i>Pseudomonas keratitis</i> . <i>Clinical and Experimental Ophthalmology</i> , 2001, 29, 179-182.	1.3	10
300	Regulatory role of IL-1beta in the expression of IL-6 and IL-8 in human corneal epithelial cells during <i>Pseudomonas aeruginosa</i> colonization. <i>Clinical and Experimental Ophthalmology</i> , 2001, 29, 171-174.	1.3	22
301	The role of IL-1 in the regulation of IL-8 and IL-6 in human corneal epithelial cells during <i>Pseudomonas aeruginosa</i> colonization. <i>Current Eye Research</i> , 2001, 23, 406-414.	0.7	23
302	A Twin Study of the Etiology of Prolonged Fatigue and Immune Activation. <i>Twin Research and Human Genetics</i> , 2001, 4, 94-102.	1.5	28
303	Long-term persistence of <i>Coxiella burnetii</i> in the host after primary Q fever. <i>Epidemiology and Infection</i> , 2000, 124, 543-549.	1.0	139
304	A homing selection hypothesis for T-cell trafficking. <i>Trends in Immunology</i> , 2000, 21, 315-317.	7.5	31
305	A serological re-evaluation of acute non-A non-B hepatitis from the early 1970s. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 668-674.	0.5	3
306	Screening for prolonged fatigue syndromes: validation of the SOFA scale. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2000, 35, 471-479.	1.6	66

#	ARTICLE	IF	CITATIONS
307	Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. <i>Medical Journal of Australia</i> , 2000, 172, 588-591.	0.8	36
308	Illness or disease? The case of chronic fatigue syndrome. <i>Medical Journal of Australia</i> , 2000, 172, 471-472.	0.8	12
309	VIP desensitizes chemokine receptors and impairs leukocyte trafficking and inflammation in vivo. <i>Gastroenterology</i> , 2000, 118, A357.	0.6	0
310	Chemokine receptor expression and function in lamina propria mononuclear cells of the human colon. <i>Gastroenterology</i> , 2000, 118, A355.	0.6	2
311	A Randomized, Double-Blind, Placebo-Controlled Trial of Moclobemide in Patients With Chronic Fatigue Syndrome. <i>Journal of Clinical Psychiatry</i> , 2000, 61, 643-648.	1.1	63
312	Transmission of hepatitis C within Australian prisons. <i>Medical Journal of Australia</i> , 1999, 171, 31-33.	0.8	51
313	Culture and characterisation of epithelial cells from human pterygia. <i>British Journal of Ophthalmology</i> , 1999, 83, 1077-1082.	2.1	35
314	Prolonged Fatigue, Anxiety and Depression: Exploring Relationships in a Primary Care Sample. <i>Australian and New Zealand Journal of Psychiatry</i> , 1999, 33, 545-552.	1.3	44
315	Phenotypic and functional characterization of lymphocytes derived from normal and HIV-1-infected human lymph nodes. <i>Clinical and Experimental Immunology</i> , 1999, 117, 92-99.	1.1	27
316	ABUNDANT EXPRESSION OF CHEMOKINES IN MALIGNANT AND INFECTIVE HUMAN LYMPHADENOPATHIES. <i>Cytokine</i> , 1999, 11, 531-540.	1.4	26
317	Complex genetic and environmental relationships between psychological distress, fatigue and immune functioning: a twin study. <i>Psychological Medicine</i> , 1999, 29, 269-277.	2.7	63
318	The temporal stability and co-morbidity of prolonged fatigue: a longitudinal study in primary care. <i>Psychological Medicine</i> , 1999, 29, 855-861.	2.7	87
319	Chronic fatigue syndrome: current concepts of pathogenesis and treatment. <i>Current Clinical Topics in Infectious Diseases</i> , 1999, 19, 135-59.	0.3	5
320	Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. <i>European Journal of Immunology</i> , 1998, 28, 1773-1784.	1.6	73
321	Chronic fatigue and chronic fatigue syndrome: shifting boundaries and attributions. <i>American Journal of Medicine</i> , 1998, 105, 7S-10S.	0.6	38
322	The Relationship between Fatigue, Psychological and Immunological Variables in Acute Infectious Illness. <i>Australian and New Zealand Journal of Psychiatry</i> , 1998, 32, 180-186.	1.3	38
323	Chronic Fatigue Syndrome: An Immunological Perspective. <i>Australian and New Zealand Journal of Psychiatry</i> , 1998, 32, 523-527.	1.3	45
324	Chemokine expression and leucocyte infiltration in Sjogren's syndrome. <i>Rheumatology</i> , 1998, 37, 779-783.	0.9	83

#	ARTICLE	IF	CITATIONS
325	In Vivo Production of Cytokines and \hat{A} (C-C) Chemokines in Human Recurrent Herpes Simplex Lesions--Do Herpes Simplex Virus-Infected Keratinocytes Contribute to Their Production?. <i>Journal of Infectious Diseases</i> , 1998, 177, 827-838.	1.9	85
326	Outpatient Continuous Intravenous Interleukin \hat{A} 2 or Subcutaneous, Polyethylene Glycol \hat{A} -Modified Interleukin \hat{A} 2 in Human Immunodeficiency Virus \hat{A} -Infected Patients: A Randomized, Controlled, Multicenter Study. <i>Journal of Infectious Diseases</i> , 1998, 178, 992-999.	1.9	95
327	A Preliminary Study to Determine the Effect of an Infusion of Cryopreserved Autologous Lymphocytes on Immunocompetence and Viral Load in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 17, 129-136.	0.3	7
328	CCR5 Expression Correlates with Susceptibility of Maturing Monocytes to Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 1998, 72, 830-836.	1.5	201
329	Mast cell activation and migration to lymph nodes during induction of an immune response in mice.. <i>Journal of Clinical Investigation</i> , 1998, 102, 1617-1626.	3.9	149
330	Molecular Biology and the Major Psychoses. <i>Australian and New Zealand Journal of Psychiatry</i> , 1997, 31, 12-16.	1.3	2
331	Molecular Biological Investigations into the Role of the NMDA Receptor in the Pathophysiology of Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 1997, 31, 17-26.	1.3	16
332	Utilising Molecular Biological and Histopathological Techniques to Study the Dopaminergic System in Patients with Melancholia. <i>Australian and New Zealand Journal of Psychiatry</i> , 1997, 31, 27-35.	1.3	7
333	Expression of TNF- \hat{A} by human plasma cells in chronic inflammation. <i>Journal of Leukocyte Biology</i> , 1997, 61, 667-678.	1.5	61
334	Cognitive deficits in patients suffering from chronic fatigue syndrome, acute infective illness or depression. <i>British Journal of Psychiatry</i> , 1997, 171, 377-381.	1.7	58
335	Chemokines in acute anterior uveitis. <i>Current Eye Research</i> , 1997, 16, 1202-1208.	0.7	106
336	Intravenous Immunoglobulin is Ineffective in the Treatment of Patients with Chronic Fatigue Syndrome. <i>American Journal of Medicine</i> , 1997, 103, 38-43.	0.6	89
337	Chemokines: leucocyte recruitment and activation cytokines. <i>Lancet, The</i> , 1997, 349, 490-495.	6.3	446
338	Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder. <i>Psychiatry Research</i> , 1996, 65, 171-178.	1.7	48
339	Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. <i>Current Eye Research</i> , 1996, 15, 1060-1068.	0.7	76
340	Fatigue in selected primary care settings: sociodemographic and psychiatric correlates. <i>Medical Journal of Australia</i> , 1996, 164, 585-588.	0.8	139
341	Cloning and expression of a second human natural killer cell granule tryptase, HNK-Tryp-2/granzyme 3. <i>Journal of Leukocyte Biology</i> , 1996, 59, 763-768.	1.5	25
342	5.17 HIV, weight loss and wasting syndrome. <i>Medical Journal of Australia</i> , 1996, 164, 549-550.	0.8	1

#	ARTICLE	IF	CITATIONS
343	Chemokines regulate T cell adherence to recombinant adhesion molecules and extracellular matrix proteins. <i>Journal of Immunology</i> , 1996, 156, 932-8.	0.4	139
344	Can the chronic fatigue syndrome be defined by distinct clinical features?. <i>Psychological Medicine</i> , 1995, 25, 925-935.	2.7	134
345	CD8+ and CD45RA+ human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1 α , interleukin-8 and RANTES. <i>European Journal of Immunology</i> , 1995, 25, 751-756.	1.6	104
346	Delayed-type hypersensitivity skin testing: Normal values in the Australian population. <i>International Journal of Immunopharmacology</i> , 1995, 17, 629-634.	1.1	17
347	Are cytokines associated with neuropsychiatric syndromes in humans?. <i>International Journal of Immunopharmacology</i> , 1995, 17, 677-683.	1.1	60
348	Biochemical correlates of in vivo cell-mediated immune dysfunction in patients with depression: A preliminary report. <i>International Journal of Immunopharmacology</i> , 1995, 17, 685-690.	1.1	23
349	Cell-mediated immune function and the outcome of chronic fatigue syndrome. <i>International Journal of Immunopharmacology</i> , 1995, 17, 691-694.	1.1	2
350	Stromelysin (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase (TIMP-1) mRNA expression in scleritis. <i>Ocular Immunology and Inflammation</i> , 1995, 3, 181-194.	1.0	5
351	Granulocyte-Colony Stimulating Factor and Lipopolysaccharide Regulate the Expression of Interleukin 8 Receptors on Polymorphonuclear Leukocytes. <i>Journal of Biological Chemistry</i> , 1995, 270, 28188-28192.	1.6	116
352	Promoter Analysis of the Human Interleukin-8 Receptor Genes, IL-8RA and IL-8RB. <i>Immunobiology</i> , 1995, 193, 334-340.	0.8	6
353	Chronic fatigue syndrome: current perspectives on evaluation and management. <i>Medical Journal of Australia</i> , 1995, 163, 314-318.	0.8	29
354	Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes.. <i>Journal of Experimental Medicine</i> , 1994, 180, 203-209.	4.2	464
355	The Economic Impact of Chronic Fatigue Syndrome. <i>Clinical Infectious Diseases</i> , 1994, 18, S162-S162.	2.9	1
356	Summary: Immunologic Studies of Chronic Fatigue Syndrome. <i>Clinical Infectious Diseases</i> , 1994, 18, S160-S161.	2.9	3
357	Summary of Public Policy and Chronic Fatigue Syndrome: A Perspective. <i>Clinical Infectious Diseases</i> , 1994, 18, S163-S165.	2.9	6
358	Cytokine Production and Fatigue in Patients with Chronic Fatigue Syndrome and Healthy Control Subjects in Response to Exercise. <i>Clinical Infectious Diseases</i> , 1994, 18, S142-S146.	2.9	49
359	The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study. <i>Annals of Internal Medicine</i> , 1994, 121, 953.	2.0	4,309
360	The treatment of chronic fatigue syndrome: Science and speculation. <i>American Journal of Medicine</i> , 1994, 96, 544-550.	0.6	84

#	ARTICLE	IF	CITATIONS
361	Immune Function in Chronic Fatigue Syndrome and Depression. <i>BioDrugs</i> , 1994, 2, 84-88.	0.7	6
362	Chronic Fatigue Syndrome. <i>Pharmacoeconomics</i> , 1994, 5, 460-464.	1.7	1
363	Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 6374-6378.	3.3	289
364	Longitudinal study of outcome of chronic fatigue syndrome. <i>BMJ: British Medical Journal</i> , 1994, 308, 756-759.	2.4	242
365	Chronic fatigue syndrome Role of psychological factors overemphasised. <i>BMJ: British Medical Journal</i> , 1994, 308, 1297-1301.	2.4	1
366	Growth hormone promotes human T cell adhesion and migration to both human and murine matrix proteins in vitro and directly promotes xenogeneic engraftment.. <i>Journal of Clinical Investigation</i> , 1994, 94, 293-300.	3.9	92
367	Structure, genomic organization, and expression of the human interleukin-8 receptor B gene. <i>Journal of Biological Chemistry</i> , 1994, 269, 11065-72.	1.6	45
368	Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide. <i>Journal of Immunology</i> , 1994, 153, 1762-8.	0.4	62
369	Genomic structure, characterization, and identification of the promoter of the human IL-8 receptor A gene. <i>Journal of Immunology</i> , 1994, 153, 2524-32.	0.4	34
370	Immunologic and psychologic therapy for patients with chronic fatigue syndrome: A double-blind, placebo-controlled trial. <i>American Journal of Medicine</i> , 1993, 94, 197-203.	0.6	188
371	Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. <i>Science</i> , 1993, 260, 355-358.	6.0	724
372	Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells.. <i>Journal of Experimental Medicine</i> , 1993, 177, 1809-1814.	4.2	697
373	Assignment of genes for interleukin-8 receptors (IL8R) A and B to human chromosome band 2q35. <i>Cytogenetic and Genome Research</i> , 1993, 63, 238-240.	0.6	22
374	Chemokines and serpentine: the molecular biology of chemokine receptors. <i>Journal of Leukocyte Biology</i> , 1993, 54, 604-612.	1.5	155
375	Impaired In Vivo Immune Responses in Patients with Melancholia. <i>British Journal of Psychiatry</i> , 1993, 162, 651-657.	1.7	80
376	Immunity and the Pathophysiology of Chronic Fatigue Syndrome. <i>Novartis Foundation Symposium</i> , 1993, 173, 176-192.	1.2	14
377	The Effects of Human Recombinant MIP-1 α , MIP-1 β , and Rantes on the Chemotaxis and Adhesion of T Cell Subsets. <i>Advances in Experimental Medicine and Biology</i> , 1993, 351, 139-146.	0.8	28
378	Immunological and Psychological Dysfunction in Patients Receiving Immunotherapy for Chronic Fatigue Syndrome. <i>Australian and New Zealand Journal of Psychiatry</i> , 1992, 26, 249-256.	1.3	7

#	ARTICLE	IF	CITATIONS
379	Immunological and Psychological Dysfunction in Patients Receiving Immunotherapy for Chronic Fatigue Syndrome. Australian and New Zealand Journal of Psychiatry, 1992, 26, 249-256.	1.3	9
380	The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine, 1992, 4, 1-5.	1.4	173
381	The economic impact of chronic fatigue syndrome. Medical Journal of Australia, 1992, 157, 599-601.	0.8	70
382	Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Trends in Immunology, 1992, 13, 169-172.	7.5	448
383	The economic impact of chronic fatigue syndrome. Medical Journal of Australia, 1992, 157, 599-601.	0.8	21
384	Chronic fatigue syndrome and depression. Lancet, The, 1991, 337, 922-923.	6.3	8
385	Muscle versus brain: chronic fatigue syndrome. Medical Journal of Australia, 1991, 154, 220-220.	0.8	0
386	Cytokine Levels in Serum and Cerebrospinal Fluid in Patients with Chronic Fatigue Syndrome and Control Subjects. Journal of Infectious Diseases, 1991, 164, 1023-1024.	1.9	69
387	Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with the chronic fatigue syndrome. Brain, 1991, 114 (Pt 1A), 85-98.	3.7	36
388	Immunoglobulin subclass abnormalities in patients with chronic fatigue syndrome. Pediatric Infectious Disease Journal, 1990, 9, 550-553.	1.1	22
389	Is there immune dysfunction in depressive disorders?. Psychological Medicine, 1990, 20, 755-761.	2.7	35
390	Prevalence of chronic fatigue syndrome in an Australian population. Medical Journal of Australia, 1990, 153, 522-528.	0.8	356
391	The Psychiatric Status of Patients with the Chronic Fatigue Syndrome. British Journal of Psychiatry, 1990, 156, 534-540.	1.7	260
392	Muscle versus brain: chronic fatigue syndrome. Medical Journal of Australia, 1990, 153, 530-534.	0.8	10
393	A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. American Journal of Medicine, 1990, 89, 561-568.	0.6	184
394	Tropical arthritis in Papua New Guinea: a reactive arthritis. Medical Journal of Australia, 1990, 152, 186-189.	0.8	13
395	Immunological abnormalities in the chronic fatigue syndrome. Medical Journal of Australia, 1990, 152, 51-52.	0.8	0
396	Muscle versus brain: chronic fatigue syndrome. Medical Journal of Australia, 1990, 153, 530-4.	0.8	2

#	ARTICLE	IF	CITATIONS
397	Immunological abnormalities in the chronic fatigue syndrome (for editorial comment, see page 117). Medical Journal of Australia, 1989, 151, 122-124.	0.8	182
398	Recurrent fever in Sjögren's syndrome. Medical Journal of Australia, 1989, 151, 163-167.	0.8	3
399	BLOOD CELL MORPHOLOGY IN CHRONIC FATIGUE SYNDROME. Lancet, The, 1989, 334, 805.	6.3	3
400	RED BLOOD CELL MORPHOLOGY IN CHRONIC FATIGUE SYNDROME. Lancet, The, 1989, 334, 217.	6.3	9
401	Recurrent fever in Sjögren's syndrome. Medical Journal of Australia, 1989, 151, 163-4, 166-7.	0.8	1
402	Snake bite on the scalp with rapid onset of envenomation. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988, 82, 347.	0.7	1
403	INTERFERON AND MYALGIC ENCEPHALOMYELITIS. Lancet, The, 1988, 331, 471.	6.3	16
404	WHAT IS MYALGIC ENCEPHALOMYELITIS?. Lancet, The, 1988, 331, 1286-1287.	6.3	125
405	HUMAN HERPESVIRUS 6 AND MYALGIC ENCEPHALOMYELITIS. Lancet, The, 1988, 331, 1059.	6.3	41
406	Muscle strength, endurance and recovery in the post-infection fatigue syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1316-1322.	0.9	90
407	ANTIBODIES TO HIV ARE PRODUCED WITHIN THE CENTRAL NERVOUS SYSTEM OF ALL SUBJECTS WITH ALL CATEGORIES OF HIV INFECTION. Australian and New Zealand Journal of Medicine, 1988, 18, 854-860.	0.5	8
408	A STUDY OF ARTHRITIS IN PAPUA NEW GUINEA. Australian and New Zealand Journal of Medicine, 1988, 18, 807-808.	0.5	6
409	Long-standing fevers in a young pregnant woman. Medical Journal of Australia, 1988, 149, 382-386.	0.8	2
410	PATHOPHYSIOLOGY OF MYALGIC ENCEPHALITIS. Lancet, The, 1987, 330, 918-919.	6.3	30
411	Acquired Immunodeficiency Syndrome (AIDS) and Sulfadiazine-Associated Acute Renal Failure. Annals of Internal Medicine, 1987, 107, 783.	2.0	24
412	Moyamoya disease causing recurrent cerebrovascular episodes in a young adult. Medical Journal of Australia, 1987, 146, 379-381.	0.8	3
413	The management of leprosy. Medical Journal of Australia, 1987, 146, 593-599.	0.8	3
414	Immigrant health screening. Medical Journal of Australia, 1987, 146, 609-609.	0.8	0

#	ARTICLE	IF	CITATIONS
415	Chronic Fatigue Syndrome: An Immunological Perspective. , 0, .		6
416	Prolonged Fatigue, Anxiety and Depression: Exploring Relationships in a Primary Care Sample. , 0, .		10
417	A Twin Study of the Etiology of Prolonged Fatigue and Immune Activation. , 0, .		2
418	Chronic Fatigue and Postinfective Fatigue Syndromes. , 0, , 371-384.		0